

# Juan M Mejia-Vilet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9126454/publications.pdf>

Version: 2024-02-01

41  
papers

1,876  
citations

471061

17  
h-index

329751

37  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1773  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and outcomes of a Hispanic lupus nephritis cohort from Mexico. <i>Rheumatology</i> , 2023, 62, 1136-1144.	0.9	4
2	The lupus nephritis management renaissance. <i>Kidney International</i> , 2022, 101, 242-255.	2.6	40
3	ANCA-associated vasculitis and IgG4-related disease overlap syndrome: a case report and literature review. <i>Immunologic Research</i> , 2022, 70, 550-559.	1.3	8
4	Comment on the Review Article. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e682-e683.	0.5	1
5	Urinary serpin-A3 is an early predictor of clinical response to therapy in patients with proliferative lupus nephritis. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, F425-F434.	1.3	4
6	Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis. <i>Clinical Rheumatology</i> , 2021, 40, 2233-2242.	1.0	11
7	Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 244-254.	2.9	27
8	Community- and Hospital-Acquired Acute Kidney Injury in COVID-19: Different Phenotypes and Dismal Prognosis. <i>Blood Purification</i> , 2021, 50, 931-941.	0.9	20
9	A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis. <i>Frontiers in Immunology</i> , 2021, 12, 621039.	2.2	11
10	Establishing a Case for Anti-complement Therapy in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 484-492.	0.4	11
11	The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. <i>Frontiers in Medicine</i> , 2021, 8, 622225.	1.2	32
12	Crystalcryoglobulinemia as a manifestation of monoclonal gammopathy of renal significance in a patient with renal cell carcinoma. <i>Journal of Onco-Nephrology</i> , 2021, 5, 140-144.	0.3	0
13	Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 937-945.	1.3	7
14	New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination. <i>Kidney International</i> , 2021, 100, 1340-1341.	2.6	48
15	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	2.6	782
16	Comment on "Clinical practice guidelines for the treatment of systemic lupus erythematosus by the Mexican College of Rheumatology". <i>Reumatología Clínica</i> , 2020, 16, 433-434.	0.2	2
17	High frequency of nocturnal hypertension in lupus nephritis: should ABPM be implemented in usual practice?. <i>Clinical Rheumatology</i> , 2020, 39, 1147-1155.	1.0	5
18	Prolonged Intermittent Renal Replacement Therapy for Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome. <i>Blood Purification</i> , 2020, 50, 1-9.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis. <i>Lupus</i> , 2020, 29, 371-378.	0.8	14
20	Validation of a renal risk score in a cohort of ANCA-associated vasculitis patients with severe kidney damage. <i>Clinical Rheumatology</i> , 2020, 39, 1935-1943.	1.0	18
21	Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1335-1347.	3.0	63
22	Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1197-1206.	0.4	24
23	Serpina3 in the Early Recognition of Acute Kidney Injury to Chronic Kidney Disease (CKD) transition in the rat and its Potentiality in the Recognition of Patients with CKD. <i>Scientific Reports</i> , 2019, 9, 10350.	1.6	32
24	Anasarca in a Patient With Polyneuropathy. <i>American Journal of Kidney Diseases</i> , 2019, 74, A11-A14.	2.1	1
25	LECT2 Amyloidosis in Kidney Transplantation: A Report of 5 Cases. <i>American Journal of Kidney Diseases</i> , 2019, 74, 563-566.	2.1	14
26	Overview of the Current Approach to Glomerular Disease Classification. , 2019, , 59-85.		1
27	Masked uncontrolled hypertension. <i>Journal of Hypertension</i> , 2019, 37, 2501-2502.	0.3	2
28	Epidemiology and Management of Lupus Nephritis. , 2019, , 727-744.		7
29	Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis. <i>Kidney International Reports</i> , 2019, 4, 40-47.	0.4	6
30	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	2.6	198
31	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	2.6	135
32	Prognostic significance of renal vascular pathology in lupus nephritis. <i>Lupus</i> , 2017, 26, 1042-1050.	0.8	37
33	Overview of the Current Approach to Glomerular Disease Classification. , 2017, , 1-28.		2
34	Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. <i>Clinical Rheumatology</i> , 2016, 35, 2219-2227.	1.0	20
35	Renal Thrombotic Microangiopathy in Proliferative Lupus Nephritis: Risk Factors and Clinical Outcomes. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 235-240.	0.5	20
36	Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. <i>Clinical Rheumatology</i> , 2016, 35, 1805-1816.	1.0	66

#	ARTICLE	IF	CITATIONS
37	Renal flare prediction and prognosis in lupus nephritis Hispanic patients. <i>Lupus</i> , 2016, 25, 315-324.	0.8	32
38	Facing the Metabolic Syndrome Epidemic in Living Kidney Donor Programs. <i>Annals of Transplantation</i> , 2016, 21, 456-462.	0.5	5
39	Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis. <i>Journal of Rheumatology</i> , 2015, 42, 2082-2091.	1.0	18
40	Radicol, a heat shock protein 90 inhibitor, reduces glomerular filtration rate. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F1044-F1051.	1.3	17
41	Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F78-F86.	1.3	112